Abstract
The in vitro susceptibilities of 16 independent, geographically distinct clinical isolates of methicillin-resistant Staphylococcus aureus to trimethoprim (TMP) in combination with sulfamethoxazole (SMX) were evaluated. Although methicillin-resistant S. aureus strains appear to be universally resistant to SMX, the combination TMP-SMX was found to be synergistic in vitro (in combination, the MICs of both drugs decreased 6- to 25-fold) as well as in vivo (5- to 6-fold reduction in TMP at 50% effective doses).
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Drug Combinations / pharmacology
-
Drug Synergism
-
Methicillin / pharmacology*
-
Mice
-
Penicillin Resistance
-
Staphylococcal Infections / drug therapy*
-
Staphylococcus aureus / drug effects*
-
Sulfamethoxazole / pharmacology*
-
Trimethoprim / pharmacology*
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Vancomycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Drug Combinations
-
Vancomycin
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Trimethoprim
-
Sulfamethoxazole
-
Methicillin